Disclosure of Results of Research Program Sample Clauses

Disclosure of Results of Research Program. The results of all work performed by a Party as part of the Research Program shall be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Ambrx and BMS will provide reports and analyses at each JRC meeting, and more frequently upon reasonable request by the JRC, detailing the current status of the Research Program, including the utilization of the Ambrx FTE resources. Within thirty (30) days following the end of each calendar quarter, Ambrx and BMS shall each exchange and provide to the JRC a written report summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding calendar quarter. In addition, upon reasonable request by a Party, the other Party will make presentations to the JRC of its activities related to the Compounds and Products to inform such Party of the details of the work done in the performance of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by BMS, for purposes of supporting the Development of a Product, Ambrx shall provide BMS with additional data, results and other information with respect to the work performed by Ambrx in the performance of the Research Program. Any reports required under this Section 3.7 may take the form of and be recorded in minutes of the JRC that will contain copies of any slides relating to the results and presented to the JRC. In addition, at BMS’ request Ambrx will transfer (within thirty (30) days of such request) to BMS all data, results, and information related to testing and studies of the Compounds (including analytical test results and non-clinical pharmacology and safety data) in the possession of Ambrx to the extent such data, results and/or information are necessary or reasonably useful for the continued Development and Commercialization of Products, including any and all Information directly relating to manufacturing methods (including related analytical methods) of the Compounds or Products.
Sample 1Sample 2Sample 3See All (14)
AutoNDA by SimpleDocs
Disclosure of Results of Research Program. The results of all work performed by the Parties as part of the Research Program will be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Regulus and AstraZeneca will provide reports and analyses at each JSC meeting, and more frequently on reasonable request by the JSC, detailing the current status of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Any reports required, excluding reports needed for submission to a Regulatory Agency, under this Section 3.9 may take the form of and be recorded in minutes of the JSC that will contain copies of any slides relating to the results and presented to the JSC. Reports needed to support regulatory submissions and updates to a Regulatory Agency will be provided in a timely manner and in a format as agreed upon by the JSC.
Sample 1Sample 2
Disclosure of Results of Research Program. The results of all work performed by the Parties as part of the Research Program will be promptly disclosed to the other Party in a reasonable manner as such results are obtained. In addition, Regulus will periodically provide Sanofi with written reports of the work performed under the Research Program, the number of FTEs committed, and the results achieved by Regulus. Regulus and Sanofi will provide reports and analyses at each JSC meeting, and more frequently on reasonable request by the JSC, detailing the current status of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by Sanofi, Regulus will provide Sanofi with additional data, results and other information with respect to the work performed by Regulus in the performance of the Research Program. Any reports required, excluding reports needed for submission to a Regulatory Agency, under this Section 3.8 may take the form of and be recorded in minutes of the JSC that will contain copies of any slides relating to the results and presented to the JSC. Reports needed to support regulatory submissions and updates to a Regulatory Agency will be provided in a timely manner and in a format as agreed upon by the JSC.
Sample 1
Disclosure of Results of Research Program. Licensor will disclose all patent applications that are filed by Licensor, and all patentable inventions, in each case which result from work done under the Research Program and that are not Background Technology. Within thirty (30) days following the end of each Calendar Quarter, Licensor shall provide to the JRC a written report summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding Calendar Quarter. In addition, upon reasonable request by Licensee, Licensor will make presentations to the JRC of its activities related to the Licensed Products to inform Licensee of the details of the work done in the performance of the Research Program, and with respect to use of the Licensed Products for any Other Indication. Upon reasonable request by Licensee, Licensor shall provide Licensee with additional data, results and other information with respect to the work performed by Licensor in the performance of the Research Program. In addition, at Licensee’s request, Licensor will transfer (within thirty (30) days of such request) to Licensee all data, results, and information related to testing and studies of Licensed Products (including analytical test results and non-clinical pharmacology and safety data) in the possession of Licensor to the extent such data, results and/or information are necessary or reasonably useful for the Exploitation of Licensed Products.
Sample 1
Disclosure of Results of Research Program. During the Research Term, Ambrx and BeiGene shall provide written reports and analyses at each JRC meeting, and more frequently upon reasonable request by the JRC, detailing all activities undertaken and all accomplishments achieved by such Party under each Research Program and the current status of each Research Program, including (a) any new data, including pre-clinical data, formulation data and manufacturing data, generated by or on behalf of such Party with respect to all Compounds; new Inventions or otherwise arising out of activities under a Research Program, (b) planned activities for the next subsequent Calendar Quarter, (c) progress against any timelines, and (d) any other aspects that the JRC may reasonably request, if any, since the previous report. In addition, during the Research Term, upon reasonable request by a Party, the other Party shall make presentations to the JRC of its activities related to the Compounds to inform such Party of the details of the activities done in the performance of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. For clarity, Ambrx shall not be required to disclose to BeiGene any proprietary information about the Ambrx Technology Platforms (i.e., description of the cell line history, Ambrx’s proprietary vector, media formulation etc.).
Sample 1
Disclosure of Results of Research Program. The results of all work performed as part of the Research Program shall be promptly disclosed to RAPT in a reasonable manner as such results are obtained. Hanmi will [***]. In addition, upon reasonable request by RAPT, Hanmi will [***]. The results, reports, analyses and other information regarding the Research Program disclosed by a Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Any reports required under this Section 3.4 (Disclosure of Results of Research Program) may take the form of and be recorded in minutes of the JSC that will contain copies of any slides relating to the results and presented to the JSC. In addition, at Hanmi’s request RAPT will transfer (within [***] of such request) to Hanmi all data (including raw data), results, and Information related to testing and studies of the Tool Compounds and/or Compounds, as applicable (including analytical test results and non-clinical pharmacology and safety data), in the Control of RAPT to the extent such data, results and/or information are necessary or reasonably useful for the conduct of the Research Program and/or the continued Development and Commercialization of Products.
Sample 1
Disclosure of Results of Research Program. Each Party will furnish to the JSC, at each JSC meeting, to the extent applicable to such Party, an update on such Party’s progress under the Research Plan for each Designated Target and any Permitted Reserved Target Activities during the relevant [***], including a summary of any material results and data generated by such Party under such Research Plan or for such Permitted Reserved Target Activities. Such Party will provide the JSC with such other results, data and other Information with respect to the activities under the Research Plan as any member of the JSC may reasonably request that are in such Party’s possession or control and are reasonably necessary or useful for the JSC to perform its responsibilities under Section 2.1(c) or for either Party to exercise its rights under this Agreement; provided that Schrödinger will not be required to transfer any results, data or other Information relating to the Xxxxxxxxxxx Xxxxxxxx, Xxxxxxxxxxx Platform Inventions, any Licensed Other Modality Compounds or Licensed Other Modality Products or the exploitation of any of the foregoing.
Sample 1
AutoNDA by SimpleDocs

Related to Disclosure of Results of Research Program

  • Disclosure of Material Information The Company covenants and agrees that neither it nor any other person acting on its behalf has provided or will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing representations in effecting transactions in securities of the Company.

  • Disclosure to numbering service providers (a) Any Finance Party may disclose to any national or international numbering service provider appointed by that Finance Party to provide identification numbering services in respect of this Agreement, the Facility and/or one or more Obligors the following information:

  • Disclosure of Material Matters Immediately upon learning thereof, report to Agent all matters materially affecting the value, enforceability or collectibility of any portion of the Collateral including, without limitation, any Borrower's reclamation or repossession of, or the return to any Borrower of, a material amount of goods or claims or disputes asserted by any Customer or other obligor.

  • Statistical Information Any third-party statistical and market-related data included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all material respects.

  • Performance of Material Contracts Perform and observe all the terms and provisions of each Material Contract to be performed or observed by it, maintain each such Material Contract in full force and effect, enforce each such Material Contract in accordance with its terms, take all such action to such end as may be from time to time requested by the Administrative Agent and, upon request of the Administrative Agent, make to each other party to each such Material Contract such demands and requests for information and reports or for action as any Loan Party or any of its Subsidiaries is entitled to make under such Material Contract, and cause each of its Subsidiaries to do so, except, in any case, where the failure to do so, either individually or in the aggregate, could not be reasonably likely to have a Material Adverse Effect.

  • Non-Disclosure of Third Party Information Executive represents and warrants and covenants that Executive shall not disclose to the Company, or use, or induce the Company to use, any proprietary information or trade secrets of others at any time, including but not limited to any proprietary information or trade secrets of any former employer, if any; and Executive acknowledges and agrees that any violation of this provision shall be grounds for Executive’s immediate termination and could subject Executive to substantial civil liabilities and criminal penalties. Executive further specifically and expressly acknowledges that no officer or other employee or representative of the Company has requested or instructed Executive to disclose or use any such third party proprietary information or trade secrets.

  • No Material Non-Public Information The Company agrees that no information provided to the Purchaser in connection with this Agreement will, upon the IPO Closing, constitute material non-public information of the Company.

  • Disclosure of Financial Information 26.1 The Customer represents and warrants that the financial information disclosed to us in his/its Application is an accurate representation of the Customer’s current financial condition.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!